Actively Recruiting
Study of BGB-58067 Alone and with Anticancer Agents to Assess Safety and Activity in Advanced Solid Tumors
Led by BeOne Medicines · Updated on 2026-10-20
695
Participants Needed
101
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying BGB-58067, a drug that blocks a protein called PRMT5, in people with advanced solid tumors that have a deficiency in a gene called MTAP. This study aims to evaluate the safety, side effects, how the drug moves and works in the body, and early signs of anti-cancer activity. The trial includes testing BGB-58067 alone, with standard cancer treatments, and with new anticancer therapies. It is a first-in-human, open-label study with dose escalation and expansion parts. Participants will receive increasing doses of BGB-58067 in various combinations, including monotherapy and with other anticancer agents or standard treatments. The study will find the best dose with manageable side effects and then test that dose in more participants. Although one combination with BG-89894 is discontinued, other combinations continue. Treatment dosing follows specific protocols and schedules determined by the study doctors. Participants will visit clinics regularly for treatment, health monitoring, blood tests, tumor scans, and imaging over about two years. Researchers will watch for side effects, measure drug levels in the blood, and assess tumor response and disease control. The study includes ongoing safety checks and evaluations to understand how the drug affects participants and their cancer over time.
CONDITIONS
Brief Title
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here